An Open-label Extension Study of Ivacaftor in Children With CF and a CFTR Gating Mutation Initiating Treatment at Age 2-5 Years (KLIMB)

Ítems similars

• Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2-5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study.
  per: Davies, Jane C., et al.
  Publicat: (2016)
• Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study.
  per: Rosenfeld, Margaret, et al.
  Publicat: (2018)
• Sweat rate analysis of ivacaftor potentiation of CFTR in non-CF adults
  per: Kim, Jeeyeon, et al.
  Publicat: (2018)
• Lumacaftor/ivacaftor combination for CF patients homozygous for Phe508del-CFTR
  per: Zhang, Weiqiang, et al.
  Publicat: (2016)
• Therapeutic benefit observed with the CFTR potentiator, ivacaftor, in a CF patient homozygous for the W1282X CFTR nonsense mutation
  per: Mutyam, Venkateshwar, et al.
  Publicat: (2016)